Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Abiraterone
Drug ID BADD_D00014
Description Abiraterone is a derivative of steroidal progesterone and is an innovative drug that offers clinical benefit to patients with hormone refractory prostate cancer. Abiraterone is administered as an acetate salt prodrug because it has a higher bioavailability and less susceptible to hydrolysis than abiraterone itself. FDA approved on April 28, 2011.
Indications and Usage Used in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer.
Marketing Status Not Available
ATC Code Not Available
DrugBank ID DB05812
KEGG ID Not Available
MeSH ID C089740
PubChem ID 132971
NDC Product Code 17337-0082; 30007-838; 42291-073; 60687-455; 69238-1165; 42291-024; 69238-1754; 54893-0070
Synonyms abiraterone | 17-(3-pyridyl)androsta-5,16-dien-3beta-ol | CB-7598 | CB 7598 | CB7598
Chemical Information
Molecular Formula C24H31NO
CAS Registry Number 154229-19-3
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Blood glucose increased13.02.02.0020.019858%Not Available
Blood insulin increased13.10.02.0010.001471%Not Available
Blood lactate dehydrogenase increased13.04.02.0020.003677%
Blood parathyroid hormone increased13.10.07.0020.001471%Not Available
Blood potassium abnormal13.11.01.0240.001471%Not Available
Blood potassium decreased13.11.01.0100.014710%Not Available
Blood potassium increased13.11.01.011--Not Available
Blood pressure abnormal13.14.03.0010.004413%Not Available
Blood pressure decreased13.14.03.002--Not Available
Blood pressure increased13.14.03.0050.031626%Not Available
Blood pressure systolic increased13.14.03.0060.002206%Not Available
Blood sodium decreased13.11.01.0120.002942%Not Available
Blood testosterone increased13.10.05.0020.005884%Not Available
Blood triglycerides increased13.12.03.001--Not Available
Blood urea increased13.13.01.006--Not Available
Body mass index decreased13.15.01.0250.001471%Not Available
Body temperature increased13.15.01.001--Not Available
Bone disorder15.02.04.004--Not Available
Bone pain15.02.01.0010.021329%
Bradycardia02.03.02.002--Not Available
Burning sensation17.02.06.001; Available
C-reactive protein increased13.09.01.007--Not Available
Cachexia16.32.03.011;; Available
Cardiac arrest02.03.04.001--
Cardiac failure02.05.01.0010.008634%
Cardiac failure congestive02.05.01.002--Not Available
Cardio-respiratory arrest22.02.06.007; Available
Cardiovascular disorder24.03.02.009; Available
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 22 Pages